Bioactive compounds derived from marine source: a potential immunotherapy treatment

References

• Abdel-Hamid, M. K., & McCluskey, A. (2014). In silico docking, molecular dynamics and binding energy insights into the bolinaquinone-clathrin terminal domain binding site. Molecules (Basel, Switzerland), 19(5), 6609–6622. https://doi.org/10.3390/MOLECULES19056609
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544. https://doi.org/10.1182/BLOOD-2008-12-195792
   PubMed Web of Science ®Google Scholar
• Almahmoud, S., & Zhong, H. A. (2019). Molecular modeling studies on the binding mode of the PD-1/PD-L1 complex inhibitors. International Journal of Molecular Sciences, 20(18), 4654. https://doi.org/10.3390/ijms20184654
   PubMed Web of Science ®Google Scholar
• Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., AuchiNCloss, H., & Sayegh, M. H. (2003). The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. The Journal of Experimental Medicine, 198(1), 63–69. https://doi.org/10.1084/JEM.20022125
   PubMed Web of Science ®Google Scholar
• Barzkar, N., Jahromi, S. T., Poorsaheli, H. B., & Vianello, F. (2019). Metabolites from marine microorganisms, micro, and macroalgae: Immense scope for pharmacology. Marine Drugs, 17(8), 464. https://doi.org/10.3390/md17080464
   PubMed Web of Science ®Google Scholar
• Brunot, A., Rioux-Leclercq, N., Bensalah, K., Verhoest, G., Edeline, J., Bellaud, P., Viel, R., Jouan, F., Laguerre, B., & Kammerer-Jacquet, S.-F. (2015). Overexpression of PD-1 and PD-L1 in renal cell carcinoma is associated with poor prognosis in metastatic patients treated with sunitinib. Annals of Oncology, 26, ii33. https://doi.org/10.1093/annonc/mdv097.2
   Google Scholar
• Carreno, B. M., & Collins, M. (2002). The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annual Review of Immunology, 20, 29–53. https://doi.org/10.1146/ANNUREV.IMMUNOL.20.091101.091806
   PubMed Web of Science ®Google Scholar
• Case, D. A., Aktulga, H. M., Belfon, K., Ben-Shalom, I., Brozell, S. R., Cerutti, D. S., Cheatham, T. E., III, Cruzeiro, V. W. D., Darden, T. A., Duke, R. E., Giambasu, G., Gilson, M. K., Gohlke, H., Goetz, A.W., Harris, R., Izadi, S., Izmailov, S.A., Jin, C., Kasavajhala, K., … Kollman, P. A. (2021). Amber 2021. University of California.
   Google Scholar
• de Barros, M., Mota Da Silva, L., Boeing, T., Somensi, L. B., Cury, B., J., de Moura Burci, L., Santin, J. R., de Andrade, S. F., Monache, F. D., & Cechinel-Filho, V. (2016). Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago Chilensis (Brazilian Arnica) and its components quercitrin and afzelin in rodents. Naunyn-Schmiedeberg’s Archives of Pharmacology, 389(4), 403–417. https://doi.org/10.1007/S00210-015-1208-0
   PubMed Web of Science ®Google Scholar
• Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021). New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med, 9, 205031212110343. https://doi.org/10.1177/20503121211034366
   Web of Science ®Google Scholar
• Duan, Y., Wu, C., Chowdhury, S., Lee, M. C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., Caldwell, J., Wang, J., & Kollman, P. e. ter (2003). A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. Journal of Computational Chemistry, 24(16), 1999–2012. https://doi.org/10.1002/JCC.10349
   PubMed Web of Science ®Google Scholar
• Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., Leroy, L., Duchemann, B., Lefebvre, C., Veillon, R., Westeel, V., Koscielny, S., Champiat, S., Ferté, C., Planchard, D., … Caramella, C. (2018). Hyperprogressive disease in patients with advanced non-small cell lung cancer treated With PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncology, 4(11), 1543–1552. https://doi.org/10.1001/JAMAONCOL.2018.3676
   PubMed Web of Science ®Google Scholar
• Gross, H., Goeger, D. E., Hills, P., Mooberry, S. L., Ballantine, D. L., Murray, T. F., Valeriote, F. A., & Gerwick, W. H. (2006). Lophocladines, bioactive alkaloids from the red alga Lophocladia sp. Journal of Natural Products, 69(4), 640–644. https://doi.org/10.1021/NP050519E
   PubMed Web of Science ®Google Scholar
• Grosso, J. F., Kelleher, C. C., Harris, T. J., Maris, C. H., Hipkiss, E. L., De Marzo, A., Anders, R., Netto, G., Getnet, D., Bruno, T. C., Goldberg, M. V., Pardoll, D. M., & Drake, C. G. (2007). LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. The Journal of Clinical Investigation, 117(11), 3383–3392. https://doi.org/10.1172/JCI31184
   PubMed Web of Science ®Google Scholar
• Guzik, K., Zak, K. M., Grudnik, P., Magiera, K., Musielak, B., Törner, R., Skalniak, L., DöMLing, A., Dubin, G., & Holak, T. A. (2017). Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. Journal of Medicinal Chemistry, 60(13), 5857–5867. https://doi.org/10.1021/ACS.JMEDCHEM.7B00293
   PubMed Web of Science ®Google Scholar
• Halgren, T. A. (1996). Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry, 17(5–6), 490–519. https://doi.org/10.1002/0470845015.CMA012M
   Web of Science ®Google Scholar
• Han, G., Chen, G., Shen, B., & Li, Y. (2013). Tim-3: An activation marker and activation limiter of innate immune cells. Frontiers in Immunology, 4, 449. https://doi.org/10.3389/FIMMU.2013.00449/BIBTEX
   PubMed Web of Science ®Google Scholar
• Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4(1), 17. https://doi.org/10.1186/1758-2946-4-17/FIGURES/14
   PubMed Web of Science ®Google Scholar
• Heo, S. J., Kim, K. N., Yoon, W. J., Oh, C., Choi, Y. U., Affan, A., Lee, Y. J., Lee, H. S., & Kang, D. H. (2011). Chromene induces apoptosis via caspase-3 activation in human leukemia HL-60 cells. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 49(9), 1998–2004. https://doi.org/10.1016/J.FCT.2011.05.011
   PubMed Web of Science ®Google Scholar
• Heo, S. J., Yoon, W. J., Kim, K. N., Oh, C., Choi, Y. U., Yoon, K. T., Kang, D. H., Qian, Z. J., Choi, I. W., & Jung, W. K. (2012). Anti-inflammatory effect of fucoxanthin derivatives isolated from Sargassum siliquastrum in lipopolysaccharide-stimulated RAW 264.7 macrophage. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association, 50(9), 3336–3342. https://doi.org/10.1016/J.FCT.2012.06.025
   PubMed Web of Science ®Google Scholar
• Ishikawa, C., Tafuku, S., Kadekaru, T., Sawada, S., Tomita, M., Okudaira, T., Nakazato, T., Toda, T., Uchihara, J.-N., Taira, N., Ohshiro, K., Yasumoto, T., Ohta, T., & Mori, N. (2008). Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. International Journal of Cancer, 123(11), 2702–2712. https://doi.org/10.1002/IJC.23860
   PubMed Web of Science ®Google Scholar
• Ismail, N. A., Matawali, A., Lee, P.-C., How, S.-E., Yazan, L. S., Goh, L. P. W., & Gansau, J. A. (2021). Mallotus mollissimus and solanum erianthum exhibit antikinase, antiphosphatase and anti-cancer properties. Journal of Pharmacy and Nutrition Sciences, 11, 93–100. https://doi.org/10.29169/1927-5951.2021.11.12
   Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics. 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 26, 677–704. https://doi.org/10.1146/ANNUREV.IMMUNOL.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006). Tissue expression of PD-L1 mediates peripheral T cell tolerance. The Journal of Experimental Medicine, 203(4), 883–895. https://doi.org/10.1084/JEM.20051776
   PubMed Web of Science ®Google Scholar
• Kim, S. K. (2013). Seafood processing by-products: Trends and applications. Seafood Processing by-Products: Trends and Applications, 9781461495901, 1–597. https://doi.org/10.1007/978-1-4614-9590-1/COVER
   Google Scholar
• Kim, B., Lee, C., Kim, Y. A., & Moon, K. C. (2020). PD-L1 expression in muscle-invasive urinary bladder urothelial carcinoma according to basal/squamous-like phenotype. Frontiers in Oncology, 10, 1. https://doi.org/10.3389/fonc.2020.527385
   PubMed Web of Science ®Google Scholar
• Kong, Z.-L., Kao, N.-J., Hu, J.-Y., & Wu, C.-S. (2016). Fucoxanthin-rich brown algae extract decreases inflammation and attenuates colitis-associated colon cancer in mice. Journal of Food and Nutrition Research, 4, 137–147. https://doi.org/10.12691/JFNR-4-3-2
   Google Scholar
• Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., ORManns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., Heinemann, V., Subklewe, M., Boeck, S., Werner, J., & von Bergwelt-Baildon, M. (2019). Advances in cancer immunotherapy 2019 - Latest trends. Journal of Experimental & Clinical Cancer Research, 38(1), 268. https://doi.org/10.1186/s13046-019-1266-0
   PubMedGoogle Scholar
• Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003). Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 33(10), 2706–2716. https://doi.org/10.1002/EJI.200324228
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341. https://doi.org/10.1016/J.DDTEC.2004.11.007
   PubMedGoogle Scholar
• Lipson, E. J., & Drake, C. G. (2011). Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17(22), 6958–6962. https://doi.org/10.1158/1078-0432.CCR-11-1595
   PubMed Web of Science ®Google Scholar
• Lotfinejad, P., Kazemi, T., Safaei, S., Amini, M., Roshani Asl, E., Baghbani, E., Sandoghchian Shotorbani, S., Jadidi Niaragh, F., Derakhshani, A., Abdoli Shadbad, M., Silvestris, N., & Baradaran, B. (2021). PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 138, 111436. https://doi.org/10.1016/J.BIOPHA.2021.111436
   PubMed Web of Science ®Google Scholar
• Lotter, M., Schilling, J., Reimann, E., & Bracher, F. (2006). First total synthesis of the 2,7-naphthyridine alkaloids Lophocladine a and B. Archiv der Pharmazie, 339(12), 677–679. https://doi.org/10.1002/ARDP.200600134
   PubMed Web of Science ®Google Scholar
• Mansour, F. A., Al-Mazrou, A., Al-Mohanna, F., Al-Alwan, M., & Ghebeh, H. (2020). PD-L1 Is Overexpressed on breast cancer stem cells through Notch3/MTOR axis. Oncoimmunology, 9(1), e1729299. https://doi.org/10.1080/2162402X.2020.1729299
   PubMed Web of Science ®Google Scholar
• Matsuno, T. (2001). Aquatic animal carotenoids. Fisheries Science, 67(5), 771–783. https://doi.org/10.1046/j.1444-2906.2001.00323.x
   Web of Science ®Google Scholar
• Menaa, F., Wijesinghe, U., Thiripuranathar, G., Althobaiti, N. A., Albalawi, A. E., Khan, B. A., & Menaa, B. (2021). Marine algae-derived bioactive compounds: A new wave of nanodrugs? Marine Drugs, 19(9), 484. https://doi.org/10.3390/md19090484
   PubMed Web of Science ®Google Scholar
• Mgltools. (2022). https://ccsb.scripps.edu/mgltools/
   Google Scholar
• Natarajan, P. M., Umapathy, V. R., Murali, A., & Swamikannu, B. (2022). Computational simulations of identified marine-derived natural bioactive compounds as potential inhibitors of oral cancer. Future Science OA, 8(3), FSO782. https://doi.org/10.2144/fsoa-2021-0148
   PubMed Web of Science ®Google Scholar
• Nhokaew, W., Kleebkaow, P., Chaisuriya, N., & Kietpeerakool, C. (2019). Programmed death ligand 1 (PD-L1) expression in epithelial ovarian cancer: A comparison of Type I and Type II tumors. Asian Pacific Journal of Cancer Prevention: APJCP, 20(4), 1161–1169. https://doi.org/10.31557/APJCP.2019.20.4.1161
   PubMedGoogle Scholar
• Nirschl, C. J., & Drake, C. G. (2013). Molecular pathways: Co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(18), 4917–4924. https://doi.org/10.1158/1078-0432.CCR-12-1972
   PubMed Web of Science ®Google Scholar
• Parry, R. v., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. v., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology, 25(21), 9543–9553. https://doi.org/10.1128/MCB.25.21.9543-9553.2005
   PubMed Web of Science ®Google Scholar
• Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., BeRNardi, R. C., Buch, R., Fiorin, G., Hénin, J., Jiang, W., McGreevy, R., Melo, M. C. R., Radak, B. K., Skeel, R. D., Singharoy, A., Wang, Y., Roux, B., Aksimentiev, A., Luthey-Schulten, Z., … Tajkhorshid, E. (2020). Scalable molecular dynamics on CPU and GPU architectures with NAMD. The Journal of Chemical Physics, 153(4), 044130. https://doi.org/10.1063/5.0014475
   PubMed Web of Science ®Google Scholar
• Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S-l., Shen, X. o. D., Boyd, Z., Hegde, P. S., Chen, D. S., & Vogelzang, N. J. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515(7528), 558–562. https://doi.org/10.1038/NATURE13904
   PubMed Web of Science ®Google Scholar
• Rigsby, R. E., & Parker, A. B. (2016). Using the PyMOL application to reinforce visual understanding of protein structure. Biochemistry and Molecular Biology Education: A Bimonthly Publication of the International Union of Biochemistry and Molecular Biology, 44(5), 433–437. https://doi.org/10.1002/BMB.20966
   PubMed Web of Science ®Google Scholar
• Rokkaku, T., Kimura, R., Ishikawa, C., Yasumoto, T., Senba, M., Kanaya, F., & Mori, N. (2013). Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma. International Journal of Oncology, 43(4), 1176–1186. https://doi.org/10.3892/IJO.2013.2019/HTML
   PubMed Web of Science ®Google Scholar
• Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine, 207(10), 2187–2194. https://doi.org/10.1084/JEM.20100643
   PubMed Web of Science ®Google Scholar
• Seeliger, D., & de Groot, B. L. (2010). Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design, 24(5), 417–422. https://doi.org/10.1007/S10822-010-9352-6
   PubMed Web of Science ®Google Scholar
• Sharif Siam, M. K., Sarker, A., & Sayeem, M. M. S. (2021). In silico drug design and molecular docking studies targeting Akt1 (RAC-Alpha Serine/Threonine-Protein Kinase) and Akt2 (RAC-Beta Serine/Threonine-Protein Kinase) proteins and investigation of CYP (Cytochrome P450) inhibitors against MAOB (Monoamine Oxidase B) for OSCC (Oral Squamous Cell Carcinoma) treatment. Journal of Biomolecular Structure & Dynamics, 39(17), 6467–6479. https://doi.org/10.1080/07391102.2020.1802335
   PubMed Web of Science ®Google Scholar
• Skalniak, L., Zak, K. M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., Szelazek, B., Kocik, J., Grudnik, P., Tomala, M., Krzanik, S., Pyrc, K., Dömling, A., Dubin, G., & Holak, T. A. (2017). Small-molecule Inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget, 8(42), 72167–72181. https://doi.org/10.18632/ONCOTARGET.20050
   PubMedGoogle Scholar
• Song, K. Y., Desar, S., Pengo, T., Shanley, R., & Giubellino, A. (2020). Correlation of MET and PD-L1 expression in malignant melanoma. Cancers (Basel), 12(7), 1847. https://doi.org/10.3390/cancers12071847
   PubMed Web of Science ®Google Scholar
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/CAAC.21660
   PubMed Web of Science ®Google Scholar
• Terasaki, M., Inoue, T., Murase, W., Kubota, A., Kojima, H., KOJoma, M., Ohta, T., Maeda, H., Miyashita, K., Mutoh, M., & Takahashi, M. (2021). A fucoxanthinol induces apoptosis in a pancreatic intraepithelial neoplasia cell. Cancer Genomics & Proteomics, 18(2), 133–146. https://doi.org/10.21873/CGP.20248
   PubMed Web of Science ®Google Scholar
• Wang, W. G., Jiang, X. N., Sheng, D., Sun, C. B., Lee, J., Zhou, X. Y., & Li, X. Q. (2019). PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma. Laboratory Investigation; a Journal of Technical Methods and Pathology, 99(10)2019 99:10, 1418–1427. https://doi.org/10.1038/s41374-019-0262-5
   PubMed Web of Science ®Google Scholar
• Wherry, E. J. (2011). T cell exhaustion. Nature Immunology, 12(6), 492–499. https://doi.org/10.1038/NI.2035
   PubMed Web of Science ®Google Scholar
• WO2015034820A1. (2015). Compounds Useful as Immunomodulators - Google Patents Available online. https://patents.google.com/patent/WO2015034820A1/en
   Google Scholar
• WO2015160641A2. (2015). Compounds Useful as Immunomodulators - Google Patents Available online. https://patents.google.com/patent/WO2015160641A2/en
   Google Scholar
• Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. (2019). AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics (Oxford, England), 35(6), 1067–1069. https://doi.org/10.1093/BIOINFORMATICS/BTY707
   PubMed Web of Science ®Google Scholar
• Yu, W., Hua, Y., Qiu, H., Hao, J., Zou, K., Li, Z., Hu, S., Guo, P., Chen, M., Sui, S., Xiong, Y., Li, F., Lu, J., Guo, W., Luo, G., & Deng, W. (2020). PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death & Disease, 11(7), 1–16. https://doi.org/10.1038/s41419-020-2701-z
   PubMed Web of Science ®Google Scholar
• Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016). Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 7(21), 30323–30335. https://doi.org/10.18632/ONCOTARGET.8730
   PubMedGoogle Scholar